Biotech entity
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. The tracked stories average 2 original sources each. Medicaid appears in 1 tracked Biotech story from February 24, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. The tracked stories average 2 original sources each. Medicaid appears in 1 tracked Biotech story from February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Medicaid. Shared-story counts are live from our verified record — not editorial picks.
While gene therapies offer curative potential for rare and genetic diseases, prohibitive costs and geographic centralization create a significant access gap. This briefing examines the systemic barriers preventing eligible patients from receiving these life-altering treatments.
Medicaid is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
